Creo Medical Group (LON:CREO) Hits New 12-Month Low – Time to Sell?

Creo Medical Group PLC (LON:CREO)’s share price hit a new 52-week low on Tuesday . The stock traded as low as GBX 15.50 ($0.19) and last traded at GBX 15.95 ($0.20), with a volume of 449749 shares. The stock had previously closed at GBX 16.13 ($0.20).

Creo Medical Group Stock Down 1.1 %

The stock’s fifty day simple moving average is GBX 21.46 and its 200-day simple moving average is GBX 28.49. The stock has a market cap of £57.70 million, a P/E ratio of -266.67 and a beta of 0.86. The company has a debt-to-equity ratio of 29.96, a quick ratio of 2.19 and a current ratio of 3.24.

Insider Activity at Creo Medical Group

In other news, insider Kevin Crofton purchased 2,916,666 shares of the business’s stock in a transaction dated Monday, October 21st. The stock was bought at an average price of GBX 24 ($0.30) per share, with a total value of £699,999.84 ($879,175.89). Also, insider Richard John Rees acquired 98,000 shares of the stock in a transaction on Thursday, October 24th. The shares were purchased at an average price of GBX 20 ($0.25) per share, with a total value of £19,600 ($24,616.93). 22.43% of the stock is currently owned by corporate insiders.

About Creo Medical Group

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.